During an in-person Community Case Forum event, Hayder Saeed, MD, discussed the RE-MIND2 matched cohort data and real-world data on the combination of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma.
August I, 2024
In an interview, Marc Braunstein, MD, PhD, reviewed key updates in multiple myeloma for chimeric antigen receptor (CAR) T-cell and bispecific antibody therapy, and discussed planning for transition of care.
During a Case-Based Roundtable® event, Robert J. Motzer, MD, evaluated the available data for cabozantinib plus nivolumab and lenvatinib plus pembrolizumab as combination therapies for non–clear cell renal cell carcinoma.
During a Case-Based Roundtable® event, Jeanne M. Palmer, MD, moderated a discussion on challenging symptoms of myelofibrosis and when to initiate treatment with JAK inhibitors.
During a Case-Based Roundtable® event, Amy DeZern, MD, MHS, discussed dosing approaches for managing anemia with luspatercept in patients with low-risk myelodysplastic syndrome.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
